Table 1: Characteristics of the subconjunctival bevacizumab (SCB) and control groups.

SCB groupControl group value

Age (years) 71.5 ± 9.273.9 ± 7.40.21
Gender
 Male12130.78
 Female1615
Ethnicity
 Caucasian26 (92.8%)27 (96.4%)
 African decent1 (3.6%)1 (3.6%)
 Asian1 (3.6%)0
 Total patients2828
Eye
 Right19170.60
 Left1113
 Total eyes3030
Diagnosis
 Open-angle glaucoma26 (86.7%)25 (83.3%)
 Ocular hypertension2 (6.7%)2 (6.7%)0.90
 Others (pigmentary,
 pseudoexfoliation)
2 (6.7%)3 (10%)
 Total eyes3030
Surgery types
 Phaco-NPGS20 (66.7%)24 (80%)
 Phacotrabeculectomy6 (20%)3 (10%)
 NPGS3 (10%)2 (6.7%)
 Trabeculectomy1 (3.3%)1 (3.3%)
 Total eyes3030
Preoperative IOP (mmHg)19.6 ± 8.921.9 ± 9.80.51
Preoperative number of medications3.0 ± 1.13.1 ± 1.00.48
Mean follow-up time (months) 16.9 ± 8.219.6 ± 11.50.16